Can Colon Cancer Cause Elevated PSA Levels?

Colon cancer can, in rare circumstances, cause a rise in prostate-specific antigen levels, though the elevation is usually modest and the mechanism is different from what drives PSA up in prostate disease. PSA is famously associated with the prostate gland, but the protein is actually produced in small quantities by a surprising number of tissues throughout the body, including parts of the gastrointestinal tract. That biological fact opens the door to a handful of scenarios in which a colorectal malignancy contributes to a higher-than-expected PSA reading, and understanding those scenarios matters for anyone trying to interpret a confusing lab result.

PSA Is Not Exclusively a Prostate Protein

The name “prostate-specific antigen” is something of a misnomer. Research using multiple detection methods has confirmed PSA expression in secretory cells of the trachea, thyroid, mammary gland, salivary glands, small intestine, and several other tissues. The concentrations are tiny compared to the prostate, representing less than one percent of what normal prostate tissue produces. But one site stood out in laboratory studies: the Paneth cells of the ileum, the final segment of the small intestine, showed pronounced PSA expression. When researchers compared PSA activity in ileum and prostate tissue, the enzyme behaved equivalently in both, breaking down the same substrates and forming the same complexes with blood proteins.¹

This means the gut already has the molecular machinery to make PSA under normal conditions. When a malignancy develops in colorectal tissue, there is a biological basis for that machinery to become dysregulated. Cancer cells frequently express proteins that their healthy parent cells would not, or they ramp up production of proteins that were previously kept at trace levels. That is the starting point for understanding how a colon tumor could push PSA into the detectable range on a blood test.

Cases Where Colon Cancer Directly Raised PSA

The most striking published example involves a man whose PSA repeatedly measured above 30 ng/mL, a level that would ordinarily raise serious concern for prostate cancer. After surgical removal of his colon cancer, his PSA dropped to 1.2 ng/mL. Although immunohistochemical staining of the tumor with PSA antibodies was not performed in that case, the investigators strongly suspected a direct relationship between the colon malignancy and the elevated reading. One proposed explanation was that the tumor produced serine proteases that cross-reacted with the PSA antibody used in the lab assay.²

That case, published in the late 1990s, remains one of the clearest demonstrations that a colon cancer can produce a measurable PSA signal in the blood. The sheer magnitude of the drop after surgery makes it hard to attribute the finding to coincidence or a concurrent prostate problem. Other research groups have since confirmed that PSA can be detected in colon cancer tissue specimens, though the clinical significance of that tissue-level expression has been less clear.³

Evidence From Women With Colorectal Cancer

Some of the most informative data on this question comes from studies of women, precisely because women lack a prostate gland. If PSA rises in a woman with colorectal cancer, the prostate is off the table as a source. A study measuring serum PSA in women with colorectal carcinoma found that free PSA levels were significantly higher compared to healthy women. About a fifth of the colorectal cancer patients tested positive for total PSA, and roughly a third tested positive for free PSA, compared to much lower rates in the healthy control group.⁴

These findings are important because they eliminate the main confounding factor. In men, you can always wonder whether an elevated PSA is coming from an enlarged or inflamed prostate rather than the colon tumor. In women, that possibility does not exist. The fact that colorectal cancer produced a detectable PSA signal in women confirms that colorectal malignancies themselves can be a source of circulating PSA, even if the absolute levels tend to be low.

Free PSA Ratios and Prognosis

An unexpected finding from this line of research is that the ratio of free to total PSA may carry prognostic value in colorectal cancer. In the study of women with colorectal carcinoma, patients whose percentage of free PSA was 35 percent or higher had significantly better cancer-specific survival than those below that threshold. The survival rate was about 83 percent in the high-free-PSA group versus roughly 56 percent in the low-free-PSA group, and that difference held up as an independent predictor even after adjusting for other variables.³

This is an area of active interest rather than established clinical practice. Nobody is using PSA ratios to guide colorectal cancer treatment decisions today. But the finding suggests that PSA dynamics in colorectal cancer are not just a laboratory curiosity. They may reflect something meaningful about tumor biology, potentially related to protease activity or the tumor’s interaction with surrounding tissue.

When the Real Problem Is Two Cancers at Once

A much more common explanation for an elevated PSA in someone with colon cancer is the presence of a separate, undiagnosed prostate cancer. These so-called synchronous or metachronous double primaries are not as rare as you might expect. In one institutional database, about 5 percent of prostate cancer patients also had colorectal cancer, with the majority diagnosed at different times rather than simultaneously.⁵

A large Korean population study looking at this from the other direction found that colorectal cancer survivors had roughly double the risk of developing prostate cancer compared to the general population. Among more than 85,000 men who had survived a first primary colorectal cancer, over 2,000 went on to develop prostate cancer during follow-up. The risk was particularly elevated in men younger than 55 at the time of their colorectal diagnosis.⁶

Case reports have also documented scenarios where both cancers are found within months of each other. Two reported cases involved men in their late 70s and 80s who were found to have prostate cancer with bone metastases alongside colon cancer, discovered nearly simultaneously during workup for other complaints.⁷

The practical takeaway here is significant: if you have colon cancer and your PSA is elevated, the PSA may not be coming from the colon tumor at all. It may be signaling a separate prostate problem that happens to coexist. Given the overlapping age ranges and shared risk factors for these two cancers, clinicians typically investigate the prostate independently rather than assuming the colon cancer explains the PSA reading.

Indirect Causes of PSA Elevation During Colon Cancer

Beyond the tumor itself producing PSA or a second cancer being present, several indirect mechanisms can push PSA up in someone dealing with a colorectal malignancy. These have nothing to do with PSA production by the colon tumor and everything to do with the downstream effects of having a pelvic or abdominal cancer.

Urinary retention is one common culprit. Colon tumors, especially those in the sigmoid colon or rectum, can press on the bladder or urethra and cause difficulty emptying the bladder. Acute urinary retention alone can roughly double serum PSA levels, as demonstrated in a study where the average PSA dropped from about 9.8 ng/mL during retention to about 5 ng/mL two weeks after relief.⁸ This effect is purely mechanical. The backed-up urine puts pressure on the prostate, causing PSA to leak into the bloodstream at a higher rate. Once the obstruction resolves, PSA comes back down.

Pelvic radiation, which is a standard treatment for rectal cancer, delivers incidental radiation to the prostate. You might expect this to push PSA up, but the evidence suggests otherwise. In a study tracking PSA in patients who received pelvic radiation for non-prostate cancers, the majority showed stable or declining PSA levels over several years. Only a small minority had any meaningful increase.⁹ Radiation tends to damage prostate tissue, which can actually suppress PSA production over time rather than increase it.

Laboratory Artifacts and False Positives

Sometimes the PSA is not genuinely elevated at all. Immunoassays, the lab tests used to measure PSA, can be fooled by substances in the blood that interfere with the antibodies in the test kit. One well-documented source of interference is heterophilic antibodies, which are proteins that bind to assay components and produce a falsely elevated signal. A case report described a patient whose PSA measured 3.2 ng/mL on one platform but was undetectable on another. The discrepancy was ultimately traced to heterophilic antibody interference, confirmed by running the sample through blocking tubes that neutralized the interfering proteins.¹⁰

This kind of artifact can occur in anyone, not just cancer patients, but it becomes clinically more confusing in someone with a known malignancy. A slightly elevated PSA in a colon cancer patient might trigger an unnecessary prostate biopsy if nobody considers the possibility that the number is a lab error. When PSA results do not match the clinical picture, running the sample on a different assay platform is a simple first step that can save a lot of worry.

Telling Prostate Cancer From Colorectal Cancer Under the Microscope

When a tumor is found in the pelvis and it is unclear whether it originated in the prostate or the colon, pathologists use a panel of immunohistochemical stains to sort it out. PSA staining is actually one of the tools in this panel, not as a blood test but as a tissue marker. In one study comparing biopsy samples, none of the colorectal adenocarcinomas stained positive for PSA, while 80 percent of prostate cancers did. Conversely, colorectal tumors reliably stained positive for CDX2 and cytokeratin 20, markers that prostate cancers almost never expressed.¹¹

This might seem contradictory: how can colon cancer produce enough PSA to raise blood levels in some cases if it does not stain positive for PSA on tissue biopsy? The answer likely has to do with sensitivity thresholds. The blood PSA test can detect extremely small amounts of circulating protein, while immunohistochemical staining on a tissue slide requires a higher concentration of the protein to light up. A tumor that sheds a small amount of PSA into the circulation might not produce enough to be visible in a tissue section. In practical terms, if a pelvic mass stains positive for PSA, it is almost certainly prostate in origin. If it stains negative, the colon is the more likely source.

The Emerging Gut-Prostate Connection

Research in recent years has begun exploring a broader relationship between gut health and prostate disease, sometimes called the gut-prostate axis. The idea is that changes in the gut microbiome, along with increased intestinal permeability (the “leaky gut” concept), may influence prostate inflammation and disease. This is relevant to the PSA question because chronic inflammation in the prostate, driven partly by signals originating in the gut, could theoretically raise PSA levels even in the absence of prostate cancer.¹²

The mechanisms here remain poorly understood. Researchers have proposed that bacterial products leaking through a compromised intestinal barrier could reach the prostate via the bloodstream and trigger inflammatory responses, which in turn could elevate PSA. Colon cancer itself, along with its treatment, can profoundly disrupt the gut microbiome and intestinal barrier function. Whether that disruption is enough to move the PSA needle in a clinically meaningful way is an open question. The gut-prostate axis is one of those ideas that makes biological sense on paper but has not yet generated the kind of hard clinical data that would change how doctors interpret a PSA test.

What To Do With an Elevated PSA and a Colon Cancer Diagnosis

If you are dealing with colon cancer and a PSA test comes back higher than expected, the first thing a urologist will want to rule out is an independent prostate problem. The statistical overlap between these two cancers in older men is real, and the most common explanation for a high PSA remains prostate disease, whether that is cancer, benign enlargement, or infection. A digital rectal exam, a repeat PSA after addressing any urinary symptoms, and potentially prostate imaging are standard next steps.

If the prostate evaluation comes back clean, the elevated PSA might be attributable to one of the mechanisms described above: ectopic production by the colon tumor, urinary retention caused by the tumor’s location, or a lab artifact. In these cases, tracking PSA over time and seeing whether it drops after cancer treatment can provide important retrospective evidence. The case where PSA fell from over 30 to 1.2 ng/mL after colon surgery is a dramatic example of that pattern. Most instances will be far subtler, with only mildly elevated values that could go either way.

One thing worth keeping in mind is that PSA is not used as a screening or monitoring tool for colorectal cancer. Standard colorectal cancer markers like CEA fill that role. If your PSA is elevated and you have colon cancer, the PSA value is telling you something about either your prostate or, less commonly, your colon tumor’s unusual biology. It is not a substitute for the conventional markers used to track colorectal disease, and chasing a mildly elevated PSA in the middle of colon cancer treatment is rarely the highest clinical priority unless the number is strikingly high or rising rapidly.